2023-03-09 07:03:18 ET
- BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q4 GAAP EPS of -$1.95 misses by $0.51 .
- Revenue of $0.24M misses by $0.84M .
-
Cash and cash equivalents totaled $193.7 million at December 31, 2022, compared to $233.0 million at December 31, 2021. To date in the first quarter of 2023, the Company utilized its existing at-the-market equity facility and received net proceeds of approximately $24 million.
The Company believes that full execution of our strategic financing with Oaktree and Qatar Investment Authority would result in a cash runway into 2025 for the Company.
For further details see:
BioXcel Therapeutics GAAP EPS of -$1.95 misses by $0.51, revenue of $0.24M misses by $0.84M